GS vs IBO · P/E 20, $324.25B cap vs rev $18.0K
Goldman Sachs Group Inc (GS) versus Impact BioMedical, Inc. (IBO) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Impact BioMedical, Inc. (IBO) is a biotechnology company listed on US.
GS does not have a complete income-statement cache yet.
Latest reported IBO revenue for 2025-09-30 was $18.0K. Net income was -$1.5M. IBO currently screens at market cap $7.6M.
GS currently screens at market cap $324.25B and trailing P/E 20.1. IBO currently screens at market cap $7.6M.
Not investment advice. Open the GS and IBO stock pages for the full models.
Not investment advice.